CD36 and glioblastoma: In microvascular endothelial cells (MVECs), arteriogenic gene reprogramming is initiated once the transcription of CD36 (an angiogenic regulator) is turned off in response to LPA/PKD-1 signaling, leading to proangiogenic and proarteriogenic responses [15, 21], whereas CD36 promotes glioblastoma progression [22] and metastatic potential of oral, breast and skin cancers in tumor initiating cells [23].